2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Non-Biological Therapies, Chemotherapy, Devices, Pharmacology, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4222 Impact of transplant conditioning intensity score on outcomes after allogeneic hematopoietic stem cell transplantation in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP of the EBMT

Sarah Kayser, MD, Arnon Nagler I, MD2, Thibeault Ferhat Berland, PhD3, Matthias Eder4, Tobias Gedde-Dahl5, Peter Pal Remenyi, MD6, Hélène Labussière-Wallet, MD7, Regis Peffault De Latour, MD, PhD8, Thomas Schroeder, MD9, Camilla Gariazzo10, Kathryn Fleming11, Francis Ayuketang Ayuk, MD12, Victoria Potter, MBBS, BSc, FRACP, FRCPA13, Vesa Lindström14, Jan Vydra, MD, PhD15, Johan A. Maertens, MD16, Mieke WH Roeven, MD, PhD17, Jurjen Versluis Sr, MD, PhD18, Mohamad Mohty, MD, PhD19, Ali Bazarbachi, MD, PhD20, Bipin Savani, MD21, Alexandros Spyridonidis22, Francesco Saraceni, MD23, Frederic Baron, MD24, Fabio Ciceri, MD25, Jaime Sanz, MD, PhD26, Eolia Brissot, MD, PhD27
1 Charité Universitätsmedizin, Berlin, Germany
2 Sheba Medical Center, Tel Hashomer, Israel
3 Sorbonne University, Paris, France
4 Hannover Medical School, Hannover, Germany
5 Oslo University Hospital, Oslo, Norway
6 Department of Hematology and Stem Cell Transplant, Budapest, Hungary
7 Hospices Civils de Lyon, Pierre Bénite, France
8 Hôpital Saint Louis, Paris, France
9 University Hospital Essen, Essen, Germany
10 AOU Città della Salute e della Scienza, Torino, Italy
11 Bristol Haematology Oncology Center, Bristol, United Kingdom
12 University Hospital Eppendorf, Hamburg, Germany
13 Kings College Hospital, London, France
14 HUCH Comprehensive Cancer Center, Helsinki, Finland
15 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
16 University Hospitals Leuven, Leuven, Belgium
17 Radboud University Medical center, Nijmegen, Netherlands
18 Erasmus MC Cancer Institute, Rotterdam, Netherlands
19 Sorbonne University, Paris, France
20 American University of Beirut Medical Center, Beirut, Lebanon
21 Vanderbilt University Medical Center, Nashville, United States
22 University of Patras, Patras, Greece
23 Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy
24 University of Liege, Liege, Belgium
25 Ospedale San Raffaele, Milano, Italy
26 University Hospital La Fe, Valencia, Spain
27 Sorbonne University, Paris, France

Background: Secondary acute myeloid leukemia (sAML) is associated with inferior outcomes compared with de novo AML, and allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative treatment for many patients. Conditioning intensity is a key determinant of both disease control and transplant-related toxicity. The transplant conditioning intensity (TCI) score (BMT 2020;55: 1114-1125) was developed to provide a more granular assessment and stratification of conditioning. While TCI has been validated across heterogeneous transplant populations, its prognostic relevance in sAML remains unknown. We therefore evaluated the impact of TCI on transplantation outcomes in adults with sAML undergoing first allo-HCT in first complete remission (CR1).

Methods: We conducted a retrospective study including adult patients (18–60 years) with sAML in CR1 who underwent first allo-HCT between 2012 and 2023 from matched sibling matched 10/10 or mismatched 9/10 unrelated, or haploidentical donors, using either peripheral blood or bone marrow grafts. Patients were categorized according to the TCI score into low (1–2), intermediate (2.5–3.5), and high (4–6) intensity groups as previously defined (BMT 2020;55: 1114-1125). The primary endpoint was overall survival (OS). Secondary endpoints included leukemia-free survival (LFS), graft-versus-host disease (GVHD)-free relapse-free survival (GRFS), relapse incidence (RI), non-relapse mortality (NRM), and acute (a) and chronic (c) GVHD. Survival outcomes were estimated using the Kaplan–Meier method and competing-risk endpoints were analyzed using cumulative incidence functions. Multivariable models were adjusted for donor type, transplant year, stem cell source, Karnofsky performance status (KPS), patient age, and transplant center.

Results: A total of 2,332 patients were included, of whom 611 (26.2%) received low TCI (1–2), 1,278 (54.8%) received intermediate TCI (2.5–3.5), and 443 (19.0%) received high TCI (4–6). Median follow-up was 4.5 years. Patients receiving high TCI were younger than those receiving intermediate and low TCI (median age 45.8 vs. 52.6 vs. 55.0 years, P<0.001), more often received bone marrow grafts (12.2% vs. 9.2% vs. 6.1%, P=0.002), had a KPS ≥90 more frequently (83.7% vs. 75.8% vs. 73.3%, P<0.001), and differed in donor type distribution (P<0.001) and transplant year (P<0.001), whereas ELN2022 cytogenetic risk, patient and donor CMV serostatus, and sex distribution were comparable across the three groups.

At 2 years, OS was 60.2%, 64.7%, and 65.2%, LFS 53.1%, 58.1%, and 57.2%, GRFS 41.8%, 46.7%, and 42.9%, RI 33.7%, 26.5%, and 26.6%, and NRM 13.2%, 15.4%, and 16.2% in the low-, intermediate-, and high-TCI groups, respectively. The cumulative incidence of grade II–IV aGVHD was 27.3%, 28.7%, and 31.0%, grade III–IV aGVHD 9.2%, 11.3%, and 11.0%, cGVHD 32.5%, 34.7%, and 33.5%, and extensive cGVHD 7.7%, 7.4%, and 9.5%, respectively.

After adjustment for donor type, transplant year, stem cell source, KPS, age, and center, TCI was not independently associated with OS, LFS, or GRFS. Compared with high TCI, low TCI was associated with a higher RI (HR 1.30, 95% CI 1.02–1.65; P=0.032), but lower NRM (HR 0.63, 95% CI 0.44–0.89; P=0.008) and grade II–IV acute GVHD (HR 0.75, 95% CI 0.57–0.98; P=0.037). No significant differences were observed between intermediate and high TCI.

Conclusions: In adults with secondary AML undergoing first allo-HCT in CR1, the TCI score was not independently associated with OS, LFS, or GRFS. Higher TCI was associated with lower relapse but higher non-relapse mortality and grade II–IV acute GVHD after adjustment for established prognostic factors, highlighting the trade-off between disease control and treatment-related toxicity.

Sarah Kayser, MD: No relevant conflicts of interest to declare.